Is Unity Software a Buy Now?
Unity Software (NYSE:U) is the company behind the popular Unity…
Sell
32
ELVN Quote, Financials, Valuation and Earnings
Last price:
$16.91
Seasonality move
:
-14.53%
Day range:
$16.27 - $20.00
52-week range:
$13.30 - $30.03
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.82x
Volume:
800.1K
Avg. volume:
352.2K
1-year change:
-25.75%
Market cap:
$873.3M
Revenue:
--
EPS (TTM):
-$1.89
Analysts' Opinion
-
Consensus RatingEnliven Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $38.29, Enliven Therapeutics has an estimated upside of 114.85% from its current price of $17.82.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $33.00 representing -85.19% downside risk from its current price of $17.82.
Fair Value
-
According to the consensus of 7 analysts, Enliven Therapeutics has 114.85% upside to fair value with a price target of $38.29 per share.
ELVN vs. S&P 500
-
Over the past 5 trading days, Enliven Therapeutics has underperformed the S&P 500 by -8.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Enliven Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enliven Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Enliven Therapeutics reported revenues of --.
Earnings Growth
-
Enliven Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Enliven Therapeutics reported earnings per share of -$0.46.
Enterprise value:
559.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$38.8M | -$83.5M | -$104.6M | -$22.7M | -$26.9M | |
| EBITDA | -$38.6M | -$83.2M | -$104.2M | -$22.7M | -$26.8M | |
| Diluted EPS | -$0.92 | -$2.18 | -$1.89 | -$0.46 | -$0.46 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $110.7M | $77.8M | $266.2M | $318.1M | |
| Total Assets | -- | $113.3M | $83.3M | $271.9M | $325.8M | |
| Current Liabilities | -- | $5.8M | $9.7M | $25.9M | $15.9M | |
| Total Liabilities | -- | $156.2M | $160.1M | $26M | $15.9M | |
| Total Equity | -- | -$42.9M | -$76.8M | $245.9M | $309.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.1M | -$61.3M | -$73.2M | -$12.5M | -$17.2M | |
| Cash From Investing | -$612K | -$148.4M | -$36M | $38.7M | $727K | |
| Cash From Financing | -$1.8M | $234.3M | $133.2M | $90K | $40M | |
| Free Cash Flow | -$32.7M | -$61.4M | -$73.2M | -$12.5M | -$17.2M | |
ELVN
Sector
Market Cap
$873.3M
$33.9M
Price % of 52-Week High
59.34%
42.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
-25.75%
-42.23%
Beta (5-Year)
1.070
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$18.97
200-day SMA
Sell
Level
$22.71
Bollinger Bands (100)
Sell
Level
18.57 - 22.57
Chaikin Money Flow
Buy
Level
26.5M
20-day SMA
Sell
Level
$18.70
Relative Strength Index (RSI14)
Sell
Level
44.48
ADX Line
Sell
Level
12.78
Williams %R
Neutral
Level
-66.8797
50-day SMA
Sell
Level
$19.19
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
42.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Stock Forecast FAQ
In the current month, ELVN has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ELVN average analyst price target in the past 3 months is $38.29.
-
Where Will Enliven Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enliven Therapeutics share price will rise to $38.29 per share over the next 12 months.
-
What Do Analysts Say About Enliven Therapeutics?
Analysts are divided on their view about Enliven Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enliven Therapeutics is a Sell and believe this share price will drop from its current level to $33.00.
-
What Is Enliven Therapeutics's Price Target?
The price target for Enliven Therapeutics over the next 1-year time period is forecast to be $38.29 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ELVN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enliven Therapeutics is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ELVN?
You can purchase shares of Enliven Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enliven Therapeutics shares.
-
What Is The Enliven Therapeutics Share Price Today?
Enliven Therapeutics was last trading at $16.91 per share. This represents the most recent stock quote for Enliven Therapeutics. Yesterday, Enliven Therapeutics closed at $17.82 per share.
-
How To Buy Enliven Therapeutics Stock Online?
In order to purchase Enliven Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Uber Stock 5X?
Uber (NYSE:UBER) has generated extremely strong returns for its investors…
How High Will Bloom Energy Stock Go?
Bloom Energy (NYSE:BE) has seen its shares surge by more…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
59
RGC alert for May 16
Regencell Bioscience Holdings [RGC] is down 4.18% over the past day.
Buy
89
BOOT alert for May 16
Boot Barn Holdings [BOOT] is up 1.14% over the past day.
Sell
43
FI alert for May 16
Fiserv [FI] is up 4.73% over the past day.
